| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
D3 Receptor
Levosulpiride-d3 targets the same biological target as Levosulpiride, which is the dopamine D2 receptor. Levosulpiride is a dopamine D2 receptor antagonist and an atypical antipsychotic agent of the benzamide class. As a deuterated compound, its primary use is as an analytical standard. |
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Levosulpiride-d3 itself is not evaluated for traditional in vitro biological activity. Its "activity" is as an analytical standard for the quantification of levosulpiride. The unlabeled levosulpiride is a dopamine D2 receptor antagonist. The deuterated version is used primarily as an internal standard. |
| ln Vivo |
Levosulpiride-d3 is not administered as a therapeutic agent in vivo. Its primary application is as an analytical standard for the quantification of levosulpiride. The compound is used in laboratory settings to measure the concentration of levosulpiride in biological samples. It is not used in animal models as an active treatment.
|
| Enzyme Assay |
Levosulpiride-d3 is used as an internal standard in analytical chemistry. Its performance is assessed by its ability to provide accurate and precise quantification of levosulpiride in complex matrices. The compound is typically analyzed by LC-MS/MS. Its isotopic purity and chemical purity are critical parameters for its use as an internal standard.
|
| Cell Assay |
Levosulpiride-d3 is used as an internal standard in the analysis of biological samples. It is added to samples containing levosulpiride to correct for variability in sample preparation and instrument performance. The labeled and unlabeled compounds are co-eluted and detected by mass spectrometry, allowing for accurate quantification of levosulpiride.
|
| Animal Protocol |
Levosulpiride-d3 is used in pharmaceutical research as an internal standard for the quantification of levosulpiride in biological samples. It is added to samples from patients or animals to accurately measure levosulpiride concentrations for pharmacokinetic and bioequivalence studies. The compound itself is not administered to animals.
|
| ADME/Pharmacokinetics |
Levosulpiride-d3 has a molecular weight of 344.44 g/mol and a molecular formula of C15H20D3N3O4S. It is a deuterated form of Levosulpiride. The compound is typically stored under recommended conditions. It is soluble in DMSO and other organic solvents. Levosulpiride is the (S)-enantiomer of sulpiride, a dopamine D2 receptor antagonist.
|
| Toxicity/Toxicokinetics |
Toxicological data for Levosulpiride-d3 are not extensively detailed, as it is a research compound. It is not intended for human or veterinary use. Standard laboratory safety precautions, including the use of personal protective equipment (PPE), should be followed when handling the compound.
|
| References | |
| Additional Infomation |
Levosulpiride-d3 is a deuterated form of Levosulpiride (RV-12309), which is the (S)-enantiomer of sulpiride, a dopamine D2 receptor antagonist and an atypical antipsychotic agent of the benzamide class. It is used as an analytical standard for the quantification of levosulpiride. It is not approved for therapeutic use.
|
| Molecular Formula |
C15H20D3N3O4S
|
|---|---|
| Molecular Weight |
344.44
|
| Exact Mass |
344.16
|
| CAS # |
124020-27-5
|
| Related CAS # |
Levosulpiride;23672-07-3
|
| PubChem CID |
12905175
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.85
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
23
|
| Complexity |
505
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[2H]C([2H])([2H])OC1=C(C=C(C=C1)S(=O)(=O)N)C(=O)NC[C@@H]2CCCN2CC
|
| InChi Key |
BGRJTUBHPOOWDU-XTRIYBSESA-N
|
| InChi Code |
InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1/i2D3
|
| Chemical Name |
N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-5-sulfamoyl-2-(trideuteriomethoxy)benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9033 mL | 14.5163 mL | 29.0326 mL | |
| 5 mM | 0.5807 mL | 2.9033 mL | 5.8065 mL | |
| 10 mM | 0.2903 mL | 1.4516 mL | 2.9033 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
